Pharmaceutical Executive

Joel Marcus, founder and executive chairman of Alexandria Real Estate Equities, and founder and CEO of Alexandria Venture Investments, discusses the drive to bring pharma manufacturing back to a company’s home country and the issues involved in doing so.

Scott Nawrocki, managing director of digital investigations and cyber defense at Nardello & Co., discusses cybersecurity in pharma, including topics from prevention to crisis management.

Editorial Director, Lisa Henderson; European and online editor, Julian Upton; Senior Editor, Elaine Quilici ;and Assistant Editors of Pharmaceutical Executive, Miranda Schmalfuhs and Andy Studna, discuss some exciting industry trends for 2021, which they recently wrote for the January issue.

Gregg Beloff, co-founder of Danforth Advisors, discusses the banner year biotech IPOs had in 2020, the drive behind that boom, and what the future of industry IPOs might look like

Rich Horgan, founder and president of Cure Rare Disease(CRD), discusses how he sprang into action when his brother was diagnosed with Duchenne muscular dystrophy, by starting a nonprofit biotech to help find a cure.

Sacha Ward, chief client officer of Point of Care Network, discusses how COVID has affected the roles of nurse practitioners and physician assistants, and why marketing managers should take a moment to understand this growing group of health care influencers.

Krystle Buntemeyer, president of SCORR Marketing, and Bharat Mehta, co-founder of PharmaCompass, discuss a new, free online tool called Pipeline Prospector, which they recently launched in collaboration. The tool aims to provide pharma executives with industry data, including deal and pipeline information, to help them make more informed decisions.

Dr. Gregg Sylvester, chief medical officer of Seqirus, discusses the importance of vaccinating against the seasonal flu amid the COVID pandemic, and how the two viruses should be considered in light of each other.

Panna Sharma, CEO of Lantern Pharma, discusses garage biotech, what he’s learned from the culture, and how it might help transform certain areas of pharma, including innovation and pricing.

Sanjeev Luther, president and CEO of Rafael Pharmaceuticals, discusses how he managed to turn around a company on the brink of bankruptcy and advance clinical trials for its lead cancer drug through COVID-19.